Immunotherapy for the treatment of colorectal cancer.
J Surg Oncol
; 123(3): 760-774, 2021 Mar.
Article
en En
| MEDLINE
| ID: mdl-33595891
ABSTRACT
Immune checkpoint inhibition (ICI) has transformed the management of metastatic colorectal cancer (mCRC) with mismatch-repair deficiency (dMMR) and microsatellite instability (MSI-H), though this constitutes on average less than 5% of mCRC, and ICI is ineffective in preserved MMR/microsatellite stable disease (pMMR/MSS). Here we review the efficacy of ICI in dMMR/MSI-H mCRC, poor response to ICI in pMMR/MSS mCRC, role for ICI in locally advanced disease, biomarkers of response, novel immunotherapies, and future directions in targeting resistance mechanisms.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
J Surg Oncol
Año:
2021
Tipo del documento:
Article